gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SXTPHealthcarePharmaceuticals

60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

$0.9563−5.32%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.97▼ 81.96% in range
Nov 3, 2025Low $0.74 · High $5.36Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

60 Degrees Pharmaceuticals closed at $0.96 on Nov 4, down 5.32%, 82.2% below its 52-week closing high. Volume of 46.1K shares was 0.05× its 20-day average (below normal).

Split-adjusted performance: -13.8% over one month, -42.4% over six months, -82.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $207.90K, down 32.5% from a year earlier, with a net margin of -1152.6%.

Short interest was 135.4K shares at the Oct 15 settlement, up 1.5% from the prior report (7.0% of float, 1.0 days to cover).

Market cap$3.4M3.5M shares
Revenue · quarter$207.9K−32.5% YoY
Diluted EPS$-0.90—
P/E · TTM—P/S 2.8×
Net margin-1,152.6%Gross 27.3%
Dividend yieldNone
52-week range0.74 – 5.36−82.2% from high
Volume46.1K0.05× 20-day avg
Volatility · 60d107.1%Annualised
Short % of float7.0%1.0 days to cover
Net cash$873.4KCash $1.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +12.9%1M −13.8%3M −16.8%6M −42.4%YTD −53.0%1Y −82.2%3Y −99.3%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum32
Revenue growth26
Net margin19
Value (low P/E)—
Size6

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short135.4K+1.5% vs prior
Days to cover1.0Settled Oct 15
% of float7.0%
Short vol. 10d38.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SXTP60 Degrees Pharmaceuticals$0.9563−5.32%−42.4%−32.5%−1152.6%—$3.4M
KALAKALA BIO$0.1781+2.95%−96.9%———$3.4MCompare
JUNSJupiter Neurosciences$2.46+1.23%−91.0%—−9380.9%—$3.2MCompare
MDCXMedicus Pharma$1.88−7.39%−88.7%———$3.6MCompare
MBIOMustang Bio$0.4138+1.07%−44.6%———$3.1MCompare
GRIGRI Bio$1.43−7.14%−39.4%———$3.1MCompare
CVKDCadrenal Therapeutics$1.06−6.19%−82.8%———$3.8MCompare
SILOSilo Pharma$1.33+3.91%−78.9%−100.0%——$2.9MCompare
ONCOOnconetix$0.6583+15.69%−85.4%−83.9%−16748.3%—$3.9MCompare

News about 60 Degrees Pharmaceuticals

All news →

No recent articles focused on 60 Degrees Pharmaceuticals. 1 articles mention it in passing.

Quick answers

What does 60 Degrees Pharmaceuticals do?
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
What is SXTP's market cap?
$3.36M, based on the Nov 4 close of $0.96.
Does 60 Degrees Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SXTP is sold short?
135.4K shares, 7.0% of float, as of Oct 15, 2026.
What sector is SXTP in?
Healthcare, in the Pharmaceuticals industry.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

HQ: Washington, DC3 employeesListed Jul 12, 202360degreespharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology